Pharmaceutical

Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s LY-3972406?

LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).

Apr 17, 2024 - 00:00
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07...

Next Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds

STAT+: BrainStorm’s case for ALS approval relies on ‘gr...

Sep 26, 2023

STAT+: How the FDA’s pandemic flexibilities boosted mental health apps — and what happens now

STAT+: How the FDA’s pandemic flexibilities boosted men...

May 11, 2023

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges

No nitrosamines: How parenteral packaging is evolving t...

May 23, 2024